About: Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein
Creator	Amaro, Rommie Barros, Emilia Casalino, Lorenzo Dommer, Abigail Fadda, Elisa Fogarty, Carl Gaieb, Zied Harbison, Aoife Taylor, Bryn
topic	covid:a8b56ef25295326d5a701be311800d353aae8019#this
Source	BioRxiv; Medline; PMC; WHO
abstract	The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 7,000,000 infections and 400,000 deaths worldwide to date. Antibody development efforts mainly revolve around the extensively glycosylated SARSCoV-2 spike (S) protein, which mediates the host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2). In the context of vaccine design, similar to many other viruses, the SARS-CoV-2 spike utilizes a glycan shield to thwart the host immune response. Here, we built a full-length model of glycosylated SARS-CoV-2 S protein, both in the open and closed states, augmenting the available structural and biological data. Multiple microsecond-long, all-atom molecular dynamics simulations were used to provide an atomistic perspective on the glycan shield and the protein structure, stability, and dynamics. End-to-end accessibility analyses outline a complete overview of the vulnerabilities of the glycan shield of SARS-CoV-2 S protein, which can be harnessed for vaccine development. In addition, a dynamic analysis of the main antibody epitopes is provided. Finally, beyond shielding, a possible structural role of N-glycans at N165 and N234 is hypothesized to modulate and stabilize the conformational dynamics of the spike’s receptor binding domain, which is responsible for ACE2 recognition. Overall, this work presents hitherto unseen functional and structural insights into the SARS-CoV-2 S protein and its glycan coat, which may be exploited by therapeutic efforts targeting this essential molecular machine.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1101/2020.06.11.146522
bibo:pmid	32577644
has license	cc-by-nc-nd
sha1sum (hex)	a8b56ef25295326d5a701be311800d353aae8019
schema:url	https://doi.org/10.1101/2020.06.11.146522
resource representing a document's title	Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein
has PubMed Central identifier	PMC7302197
has PubMed identifier	32577644
schema:publication	bioRxiv
resource representing a document's body	covid:a8b56ef25295326d5a701be311800d353aae8019#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/a8b56ef25295326d5a701be311800d353aae8019
is schema:about of	named entity 'insights' named entity 'development' named entity 'binding domain' named entity '28S' named entity 'MULTIPLE' named entity 'PROVIDED' named entity 'FUNCTIONAL' named entity 'MORE THAN' named entity 'TO PROVIDE' named entity 'ONGOING' named entity 'EPITOPES' named entity 'BEYOND' named entity 'glycan' named entity 'enzyme' named entity 'structural' named entity 'open' named entity 'protein structure' named entity 'protein' named entity 'glycosylated' named entity 'structural' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'worldwide' named entity 'Overall' named entity 'context' named entity 'protein' named entity 'glycosylated' named entity 'protein' named entity 'protein' named entity 'cell entry' named entity 'COVID-19 pandemic' named entity 'N165' named entity 'SARS-CoV-2' named entity 'protein structure' named entity 'SARS-CoV-2' named entity 'microsecond' named entity 'vaccine' named entity 'gray line' named entity 'NTD' named entity 'electrostatic interactions' named entity 'COVID-19' named entity 'HR2' named entity 'ACE2' named entity 'N-glycans' named entity 'N165' named entity 'PDB' named entity 'Open and Closed systems' named entity 'RBD' named entity 'phospholipids' named entity 'gray line' named entity 'RBDs' named entity '1.01325 bar' named entity 'protein' named entity 'protein glycosylation' named entity 'fucosylation' named entity 'pseudotyped viruses' named entity 'cytoplasmic' named entity 'protein' named entity 'ASA' named entity 'cytoplasmic' named entity 'Mutant' named entity 'secondary structure' named entity 'ASA' named entity 'atom' named entity 'chitobiose' named entity 'N165' named entity 'antibodies' named entity 'lipid' named entity 'lipid' named entity 'protein' named entity 'GUI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software